×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

UK Depression Screening Mental Health Market

ID: MRFR/HC/54515-HCR
200 Pages
Rahul Gotadki
October 2025

UK Depression Screening Mental Health Market Research Report: By Indication (Major Depressive Disorder, Anxiety Distress, Bipolar Disorder, Psychotic Disorders, Others), By Diagnosis (Psychological Tests, Blood Tests, Pharmacogenomic Testing, Others) andBy End User (Hospitals and Clinics, Home-based, Research and Academic Institutes)- Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

UK Depression Screening Mental Health Market Infographic
Purchase Options

UK Depression Screening Mental Health Market Summary

As per MRFR analysis, the UK depression screening and mental health market size was estimated at 27.39 USD Million in 2024. The UK depression screening-mental-health market is projected to grow from 29.01 USD Million in 2025 to 51.37 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.88% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The UK depression screening-mental-health market is experiencing a transformative shift towards integrated and technologically advanced solutions.

  • Increased awareness and education regarding mental health issues is driving demand for screening services.
  • Technological advancements in screening tools are enhancing the accuracy and efficiency of depression assessments.
  • Integration of mental health screening into primary care settings is becoming more prevalent, facilitating early intervention.
  • The rising prevalence of mental health disorders and government initiatives are key drivers propelling market growth.

Market Size & Forecast

2024 Market Size 27.39 (USD Million)
2035 Market Size 51.37 (USD Million)
CAGR (2025 - 2035) 5.88%

Major Players

UnitedHealth Group (US), Anthem (US), Cigna (US), Kaiser Permanente (US), Teladoc Health (US), Mayo Clinic (US), HCA Healthcare (US), Mental Health America (US)

UK Depression Screening Mental Health Market Trends

The depression screening-mental-health market is currently experiencing notable shifts, driven by an increasing awareness of mental health issues and the importance of early detection. Recent initiatives by government bodies and health organizations emphasize the necessity of regular screening for depression, aiming to reduce stigma and improve access to mental health services. This heightened focus appears to be fostering a more supportive environment for individuals seeking help, which may lead to an uptick in screening rates. Furthermore, advancements in technology, such as telehealth services and digital screening tools, are likely enhancing accessibility and convenience for patients, thereby encouraging more individuals to engage with mental health resources. In addition, the integration of mental health screening into primary care settings is becoming more prevalent. This approach seems to facilitate a holistic view of patient health, allowing for earlier intervention and more comprehensive care. As the landscape evolves, it is essential to monitor how these trends impact the overall effectiveness of depression screening and the subsequent treatment pathways available to patients. The ongoing commitment to improving mental health services indicates a positive trajectory for the depression screening-mental-health market, suggesting that future developments may further enhance the quality of care provided to those in need.

Increased Awareness and Education

There is a growing emphasis on mental health education, which appears to be reducing stigma associated with seeking help. Campaigns led by health organizations are likely encouraging individuals to participate in screening, thereby increasing overall engagement with mental health services.

Technological Advancements in Screening

The rise of digital tools and telehealth services is transforming how depression screening is conducted. These innovations seem to provide greater accessibility, allowing individuals to undergo assessments from the comfort of their homes, which may lead to higher participation rates.

Integration into Primary Care

The incorporation of mental health screening into routine primary care practices is becoming more common. This trend suggests a shift towards a more comprehensive approach to health, where mental well-being is prioritized alongside physical health, potentially improving early detection and treatment outcomes.

UK Depression Screening Mental Health Market Drivers

Government Initiatives and Funding

Government initiatives aimed at improving mental health services play a significant role in driving the depression screening-mental-health market. The UK government has committed substantial funding to mental health programs, with an investment of over £2 billion in mental health services announced recently. These initiatives focus on enhancing access to screening and treatment for depression, particularly in underserved populations. By prioritizing mental health, the government encourages healthcare providers to adopt standardized screening practices, which may lead to earlier diagnosis and intervention. This proactive approach not only benefits individuals but also alleviates the broader societal burden of untreated mental health conditions. As a result, the depression screening-mental-health market is likely to experience sustained growth due to these supportive policies.

Growing Public Awareness and Advocacy

Public awareness and advocacy for mental health issues are crucial drivers of the depression screening-mental-health market. Campaigns aimed at reducing stigma surrounding mental health have gained momentum in recent years, encouraging individuals to seek help. This cultural shift is reflected in the increasing number of people willing to participate in screening programs. Organizations and charities are actively promoting the importance of mental health screenings, which may lead to higher engagement rates among the population. As awareness continues to grow, the demand for accessible and effective screening methods is likely to rise. This trend not only benefits individuals but also supports the overall development of the depression screening-mental-health market, as more resources are allocated to meet the needs of those seeking assistance.

Increased Focus on Preventative Healthcare

The shift towards preventative healthcare is influencing the depression screening-mental-health market significantly. There is a growing recognition that early intervention can mitigate the long-term effects of mental health disorders, including depression. This trend is reflected in the increasing integration of mental health screenings into routine health assessments. Healthcare providers are now more inclined to incorporate mental health evaluations as part of comprehensive care, which may lead to higher detection rates of depression. The emphasis on preventative measures aligns with public health goals, potentially reducing the overall healthcare costs associated with untreated mental health issues. As this focus on prevention continues, the depression screening-mental-health market is expected to expand, driven by the demand for early detection and intervention strategies.

Rising Prevalence of Mental Health Disorders

The increasing prevalence of mental health disorders in the UK is a critical driver for the depression screening-mental-health market. Recent data indicates that approximately 1 in 6 adults experience mental health issues, with depression being one of the most common conditions. This rising incidence necessitates effective screening methods to identify individuals in need of support. As awareness grows, healthcare providers are more likely to implement screening protocols, thereby expanding the market. The National Health Service (NHS) has recognized the importance of early detection, which may lead to increased funding and resources allocated to mental health services. Consequently, the depression screening-mental-health market is poised for growth as more individuals seek help and healthcare systems adapt to meet this demand.

Technological Innovations in Screening Tools

Technological innovations are transforming the landscape of the depression screening-mental-health market. The development of digital tools and mobile applications for mental health assessment is gaining traction in the UK. These technologies offer convenient and accessible screening options, allowing individuals to assess their mental health from the comfort of their homes. Furthermore, advancements in artificial intelligence and machine learning are enhancing the accuracy of screening tools, enabling more precise identification of depression symptoms. As these technologies become more widely adopted, they are likely to increase the overall efficiency of mental health services. The integration of technology into screening processes may also attract younger demographics, further expanding the market's reach and impact.

Market Segment Insights

By Indication: Major Depressive Disorder (Largest) vs. Anxiety Distress (Fastest-Growing)

The UK depression screening-mental-health market exhibits a varied distribution of segments, with Major Depressive Disorder capturing the largest share due to its prevalence among the population. Following closely, Anxiety Distress represents a significant portion of the market and is observed to be expanding rapidly as mental health awareness increases. Bipolar Disorder and Psychotic Disorders hold smaller shares, while 'Others' include various less common disorders, contributing to a niche yet vital part of the market. Growth trends in this segment are largely driven by heightened awareness of mental health issues and the growing demand for effective screening tools. The rise in anxiety-related disorders, particularly in the aftermath of recent global events, has propelled Anxiety Distress to the forefront, marking it as the fastest-growing segment. On the other hand, Major Depressive Disorder remains a dominant concern, bolstered by ongoing research and innovations in treatment methodologies, ensuring its continued relevance in the market.

Major Depressive Disorder: Dominant vs. Anxiety Distress: Emerging

Major Depressive Disorder is characterized by its widespread prevalence and significant impact on daily functioning, leading it to be regarded as the dominant segment within the UK depression screening-mental-health market. Its established position is supported by robust research, diagnostic tools, and treatment options aimed specifically at managing this disorder. Conversely, Anxiety Distress is emerging rapidly, driven by surging public awareness and the societal impact of stressors. Innovations in screening and therapeutic approaches for anxiety reflect a shifting focus within the mental health landscape. This evolution indicates a growing recognition of its effects on overall well-being, positioning Anxiety Distress as a pivotal area for future growth and investment.

By Diagnosis: Psychological Tests (Largest) vs. Pharmacogenomic Testing (Fastest-Growing)

In the UK depression screening-mental-health market, Psychological Tests dominate the diagnosis segment, capturing a significant share of the market. Blood Tests and Others follow, with Pharmacogenomic Testing emerging as a notable competitor in recent years. The distribution highlights a strong preference for psychological assessments, signifying their established role in the diagnostic process. Growth trends indicate a rising demand for advanced diagnostic methods, particularly for Pharmacogenomic Testing, which is gaining traction due to its potential for personalized treatment. The shift towards holistic mental health care is driving this evolution, as professionals seek more tailored approaches. Technological advancements and increasing awareness around the impact of genetics on mental health contribute to the burgeoning interest in this segment.

Psychological Tests (Dominant) vs. Pharmacogenomic Testing (Emerging)

Psychological Tests stand out as the dominant approach in the UK depression screening-mental-health market, renowned for their ability to provide comprehensive evaluations of mental health conditions. Their established methodologies, combined with robust clinical validation, make them the preferred choice among mental health professionals. Conversely, Pharmacogenomic Testing is an emerging segment, focusing on understanding how an individual's genetic makeup affects their response to medications. This innovative approach is capturing attention due to its potential in enhancing treatment efficacy. As healthcare shifts towards personalized medicine, both segments bring unique value to the diagnosis landscape, with Psychological Tests ensuring accurate assessments while Pharmacogenomic Testing paves the way for customized therapeutic strategies.

By End User: Hospitals and Clinics (Largest) vs. Home-based (Fastest-Growing)

In the UK depression screening-mental-health market, the segment distribution shows that hospitals and clinics hold a significant share, primarily due to their established infrastructure and resources for mental health care. This segment serves a broad demographic, offering comprehensive screening services and associated treatments within a structured environment. On the other hand, the home-based segment, which is rapidly gaining traction, caters to the increasing demand for convenient and accessible mental health solutions, especially post-pandemic, as more patients prefer remote assessments. Growth trends indicate that the home-based segment is the fastest-growing due to technological advancements in telehealth and heightened awareness of mental health issues. Factors contributing to this growth include changing consumer preferences for at-home care, the effectiveness of digital screening tools, and supportive government policies promoting mental health initiatives. As more people seek personalized care, the demand for both traditional and innovative approaches continues to shape the landscape of mental health screening in the UK.

Hospitals and Clinics: Dominant vs. Home-based: Emerging

The hospitals and clinics segment of the UK depression screening-mental-health market is characterized by its established capabilities in comprehensive patient management, combining screening with immediate access to therapeutic interventions. These facilities often employ a multidisciplinary approach involving psychiatrists, psychologists, and counselors. Conversely, the home-based segment is emerging strongly, driven by the convenience of at-home assessments and the integration of technology in mental health care. This segment is popular among younger demographics who prefer privacy and flexibility, utilizing apps and online platforms for their mental health screening needs. Both segments reflect contrasting yet complementary approaches in addressing depression, showcasing the evolving nature of mental health care delivery.

Get more detailed insights about UK Depression Screening Mental Health Market

Key Players and Competitive Insights

The depression screening-mental-health market in the UK is characterized by a dynamic competitive landscape, driven by increasing awareness of mental health issues and the growing demand for accessible screening solutions. Key players such as UnitedHealth Group (US), Cigna (US), and Teladoc Health (US) are strategically positioned to leverage digital health innovations and telehealth services. These companies focus on enhancing patient engagement through technology, thereby reshaping the competitive environment. Their operational strategies emphasize partnerships with local healthcare providers and investments in AI-driven solutions to improve diagnostic accuracy and treatment personalization.

The market structure appears moderately fragmented, with a mix of established players and emerging startups. Companies are adopting various business tactics, including localizing services to meet regional needs and optimizing supply chains to enhance service delivery. This collective influence of key players fosters a competitive atmosphere where innovation and customer-centric approaches are paramount.

In October 2025, UnitedHealth Group (US) announced a partnership with a leading UK-based mental health app developer to integrate advanced screening tools into their existing telehealth platform. This strategic move is likely to enhance their service offerings, allowing for more comprehensive mental health assessments and timely interventions, thus positioning them favorably in the market.

In September 2025, Cigna (US) launched a new initiative aimed at expanding access to mental health resources in underserved communities across the UK. This initiative, which includes partnerships with local organizations, underscores Cigna's commitment to addressing health disparities and could significantly enhance their market presence by fostering community trust and engagement.

In August 2025, Teladoc Health (US) expanded its mental health services by acquiring a UK-based teletherapy platform. This acquisition is expected to bolster Teladoc's capabilities in providing personalized mental health care, reflecting a broader trend of consolidation in the market as companies seek to enhance their service portfolios and reach a wider audience.

As of November 2025, current competitive trends indicate a strong emphasis on digitalization, with companies increasingly integrating AI technologies to streamline operations and improve patient outcomes. Strategic alliances are becoming more prevalent, as firms recognize the value of collaboration in enhancing service delivery and expanding market reach. Looking ahead, competitive differentiation is likely to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and reliable supply chains, thereby fostering a more sustainable and responsive market environment.

Key Companies in the UK Depression Screening Mental Health Market market include

Industry Developments

The UK Depression Screening Mental Health Market has seen significant developments recently. Notably, the National Health Service (NHS) continues to enhance its mental health services, integrating digital technologies to assess and screen for depression more effectively. Noteworthy collaborations have arisen among organizations such as Samaritans and Mind to improve awareness and accessibility of mental health resources. In September 2023, Talkspace announced a strategic partnership with NHS to provide virtual therapy sessions aimed at reaching underserved populations across the country. These advancements are vital, given the increasing recognition of mental health issues exacerbated by the COVID-19 pandemic. 

Furthermore, Psychology Aotearoa and BetterHelp have been expanding their presence in the UK, demonstrating a growing demand for accessible mental health services. In recent years, the market has experienced a notable valuation increase, driven by heightened awareness and destigmatization of mental health, along with support from organizations like Bupa and The Royal College of Psychiatrists. The robust growth trajectory indicates an ongoing commitment from stakeholders to prioritize mental health screening and support services across the UK.

Future Outlook

UK Depression Screening Mental Health Market Future Outlook

The Depression Screening Mental Health Market is projected to grow at a 5.88% CAGR from 2024 to 2035, driven by increasing awareness, technological advancements, and policy support.

New opportunities lie in:

  • Development of AI-driven diagnostic tools for early detection
  • Expansion of telehealth services for remote screening
  • Integration of mental health screenings in workplace wellness programs

By 2035, the market is expected to be robust, reflecting significant advancements and increased accessibility.

Market Segmentation

UK Depression Screening Mental Health Market End User Outlook

  • Hospitals and Clinics
  • Home-based
  • Research and Academic Institutes

UK Depression Screening Mental Health Market Diagnosis Outlook

  • Psychological Tests
  • Blood Tests
  • Pharmacogenomic Testing
  • Others

UK Depression Screening Mental Health Market Indication Outlook

  • Major Depressive Disorder
  • Anxiety Distress
  • Bipolar Disorder
  • Psychotic Disorders
  • Others

Report Scope

MARKET SIZE 2024 27.39(USD Million)
MARKET SIZE 2025 29.01(USD Million)
MARKET SIZE 2035 51.37(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR) 5.88% (2024 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Million
Key Companies Profiled UnitedHealth Group (US), Anthem (US), Cigna (US), Kaiser Permanente (US), Teladoc Health (US), Mayo Clinic (US), HCA Healthcare (US), Mental Health America (US)
Segments Covered Indication, Diagnosis, End User
Key Market Opportunities Integration of digital tools for enhanced accessibility in the depression screening-mental-health market.
Key Market Dynamics Rising demand for digital screening tools drives innovation in the depression screening-mental-health market.
Countries Covered UK

Leave a Comment

FAQs

What is the expected market size of the UK Depression Screening Mental Health Market in 2024?

The UK Depression Screening Mental Health Market is expected to be valued at 39.42 million USD in 2024.

What is the projected market size for the UK Depression Screening Mental Health Market by 2035?

By 2035, the market is anticipated to reach a valuation of 72.46 million USD.

What is the estimated CAGR of the UK Depression Screening Mental Health Market from 2025 to 2035?

The expected compound annual growth rate (CAGR) for this market is 5.69% from 2025 to 2035.

Which segment is projected to dominate the UK Depression Screening Mental Health Market in 2024?

The Major Depressive Disorder segment is projected to be valued at 14.5 million USD in 2024.

What will be the market value for Anxiety Distress in the UK Depression Screening Mental Health Market by 2035?

The market value for Anxiety Distress is expected to reach 18.8 million USD by 2035.

Who are the key players in the UK Depression Screening Mental Health Market?

Major players include NHS, Samaritans, Mind, Aetna, Talkspace, and BetterHelp among others.

What is the expected market value for Bipolar Disorder in 2024?

The Bipolar Disorder segment is expected to be valued at 5.5 million USD in 2024.

What will the market size for Psychotic Disorders be in 2035?

The market size for Psychotic Disorders is projected to reach 8.4 million USD by 2035.

What growth trends are anticipated in the UK Depression Screening Mental Health Market?

Emerging trends include increased emphasis on digital health solutions and personalized care approaches.

What challenges might impact the UK Depression Screening Mental Health Market in the coming years?

Challenges may include funding constraints and variations in health policy across regions affecting accessibility.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions